5 Stem Cell Therapy Clinics in Boise, Idaho

Idaho cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Idaho for orthopedic, neurologic, or longevity indications are Section 351 biologics that lack FDA approval. The end of FDA's enforcement discretion in May 2021 means Idaho clinics outside Section 361 have direct federal exposure.

• Idaho Medical Practice Act, Idaho Code Title 54, Chapter 18
  Establishes physician licensure under the Idaho Board of Medicine and authority to discipline regenerative medicine providers.
• Idaho Naturopathic Medical Act, Idaho Code Title 54, Chapter 51
  Provides limited naturopathic registration; injection scope is narrow and excludes most cellular biologics.
• Idaho Pharmacy Act, Idaho Code Title 54, Chapter 17
  Regulates compounding pharmacies aligned with federal 503A and 503B standards.

The FDA has corresponded with Idaho providers offering cellular therapies, but no large-scale federal injunction has been brought against an Idaho clinic. The Idaho Board of Medicine can discipline physicians for unprofessional conduct including misleading regenerative medicine advertising. The Idaho Attorney General can pursue deceptive marketing under the Idaho Consumer Protection Act. Idaho's smaller market means enforcement is less frequent than in California or Florida, but federal warning letters apply nationally and Idaho clinics that source unapproved cellular products from out-of-state suppliers face the same regulatory risk.